T. Rowe Price Investment Management Inc. Sells 167,663 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX)

T. Rowe Price Investment Management Inc. decreased its holdings in Nurix Therapeutics, Inc. (NASDAQ:NRIX - Free Report) by 6.6% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,380,428 shares of the company's stock after selling 167,663 shares during the period. T. Rowe Price Investment Management Inc. owned about 3.14% of Nurix Therapeutics worth $44,848,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in the stock. FMR LLC lifted its position in Nurix Therapeutics by 1,711.9% in the 4th quarter. FMR LLC now owns 10,634,231 shares of the company's stock worth $200,349,000 after buying an additional 10,047,329 shares in the last quarter. Lord Abbett & CO. LLC purchased a new stake in shares of Nurix Therapeutics during the third quarter worth $7,879,000. Vanguard Group Inc. boosted its position in Nurix Therapeutics by 8.3% during the fourth quarter. Vanguard Group Inc. now owns 4,345,266 shares of the company's stock valued at $81,865,000 after purchasing an additional 333,452 shares during the last quarter. Norges Bank acquired a new stake in Nurix Therapeutics during the fourth quarter valued at $6,006,000. Finally, Nikko Asset Management Americas Inc. increased its position in Nurix Therapeutics by 42.8% in the 4th quarter. Nikko Asset Management Americas Inc. now owns 789,222 shares of the company's stock worth $14,869,000 after purchasing an additional 236,620 shares during the last quarter.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on the company. Leerink Partners initiated coverage on Nurix Therapeutics in a research note on Monday, March 17th. They issued a "market perform" rating and a $16.00 price target for the company. Stifel Nicolaus lowered their target price on shares of Nurix Therapeutics from $36.00 to $35.00 and set a "buy" rating on the stock in a research report on Wednesday, April 9th. JPMorgan Chase & Co. cut their target price on Nurix Therapeutics from $31.00 to $30.00 and set an "overweight" rating on the stock in a report on Wednesday, January 29th. Wells Fargo & Company decreased their price target on Nurix Therapeutics from $32.00 to $25.00 and set an "overweight" rating for the company in a research note on Wednesday, April 9th. Finally, HC Wainwright reissued a "buy" rating and issued a $36.00 price objective on shares of Nurix Therapeutics in a research note on Wednesday, April 2nd. Three analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $30.44.

Nurix Therapeutics Price Performance

Shares of NASDAQ NRIX traded up $0.09 during trading hours on Wednesday, reaching $11.53. The stock had a trading volume of 747,531 shares, compared to its average volume of 892,651. The company has a market cap of $879.00 million, a price-to-earnings ratio of -3.99 and a beta of 2.23. Nurix Therapeutics, Inc. has a twelve month low of $8.18 and a twelve month high of $29.56. The business's fifty day moving average is $12.35 and its two-hundred day moving average is $18.23.

Nurix Therapeutics (NASDAQ:NRIX - Get Free Report) last announced its quarterly earnings data on Tuesday, April 8th. The company reported ($0.67) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.72) by $0.05. Nurix Therapeutics had a negative net margin of 354.85% and a negative return on equity of 53.65%. The company had revenue of $18.45 million during the quarter, compared to analysts' expectations of $12.78 million. During the same quarter in the prior year, the company posted ($0.76) EPS. Sell-side analysts forecast that Nurix Therapeutics, Inc. will post -2.99 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, CFO Houte Hans Van sold 2,811 shares of the firm's stock in a transaction that occurred on Thursday, January 30th. The stock was sold at an average price of $19.85, for a total transaction of $55,798.35. Following the completion of the transaction, the chief financial officer now owns 39,549 shares in the company, valued at $785,047.65. This trade represents a 6.64 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Gwenn Hansen sold 3,690 shares of the company's stock in a transaction on Thursday, January 30th. The shares were sold at an average price of $19.85, for a total value of $73,246.50. Following the completion of the sale, the insider now owns 55,937 shares in the company, valued at $1,110,349.45. This trade represents a 6.19 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 12,326 shares of company stock worth $213,449 over the last quarter. Company insiders own 7.40% of the company's stock.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.